1. Design of Organo-Peptides As Bipartite PCSK9 Antagonists.
- Author
-
Burdick DJ, Skelton NJ, Ultsch M, Beresini MH, Eigenbrot C, Li W, Zhang Y, Nguyen H, Kong-Beltran M, Quinn JG, and Kirchhofer D
- Subjects
- Binding Sites, Crystallography, X-Ray, Drug Design, Hep G2 Cells, Humans, Molecular Structure, Peptides chemistry, Peptides metabolism, Proprotein Convertase 9 chemistry, Proprotein Convertase 9 metabolism, Protein Binding, Serine Proteinase Inhibitors chemistry, Serine Proteinase Inhibitors metabolism, PCSK9 Inhibitors, Peptides pharmacology, Serine Proteinase Inhibitors pharmacology
- Abstract
Proprotein convertase subtilisin/kexin 9 (PCSK9) has become an important therapeutic target for lipid lowering, since it regulates low-density lipoprotein cholesterol (LDL-c) levels by binding to liver LDL receptors (LDLR) and effecting their intracellular degradation. However, the development of small molecule inhibitors is hampered by the lack of attractive PCSK9 target sites. We recently discovered helical peptides that are able to bind to a cryptic groove site on PCSK9, which is situated in proximity to the main LDLR binding site. Here, we designed potent bipartite PCSK9 inhibitors by appending organic moieties to a helical groove-binding peptide to reach a hydrophobic pocket in the proximal LDLR binding region. The ultimately designed 1-amino-4-phenylcyclohexane-1-carbonyl extension improved the peptide affinity by >100-fold, yielding organo-peptide antagonists that potently inhibited PCSK9 binding to LDLR and preserved cellular LDLR. These new bipartite antagonists have reduced mass and improved potency compared to the first-generation peptide antagonists, further validating the PCSK9 groove as a viable therapeutic target site.
- Published
- 2020
- Full Text
- View/download PDF